Home Latest Articles
Latest Articles
  • Jiahao HU, Yuhan LIU, Xingming PAN, Chunlin JIN, Fen LI
    World Clinical Drug. 2023, 44(9): 981-989.
    Objective

    To evaluate the cost-effectiveness analysis of nintedanib esylate in the treatment of idiopathic pulmonary fibrosis (IPF).

    Methods

    From the perspective of Chinese healthcare system, a Markov model was constructed to evaluate the cost-effectiveness of nintedanib esylate compared with pirfenidone in the treatment of IPF patients. The model cycle was one month using a lifetime horizon. The discount rate of both cost and effectiveness was 5%. One-way sensitivity analysis, probabilistic sensitivity analysis and scenario analysis were used to verify the robustness of the base case results.

    Results

    The results of the base case showed that compared with generic pirfenidone, nintedanib esylate had lower costs and higher quality-adjusted life years output in the treatment of IPF patients, which had absolute advantages and was a more economical program. The conclusion was verified in one-way sensitivity analysis, probabilistic sensitivity analysis and scenario analysis.

    Conclusion

    Nintedanib esylate is a cost-effective alternative compared with generic pirfenidone in Chinese patients with IPF.

  • Yaan ZHANG, Yukun WANG, Wei SHEN
    World Clinical Drug. 2023, 44(9): 990-993.

    Zuranolone is a new neuroactive steroid drug, which acts on the positive allosteric modulation of γ-aminobutyric acid type A receptor, and is expected to become a new treatment for depression. The results of phase Ⅲ clinical trials showed that zuranolone could rapidly improve depressive symptoms with the treatment of oral administration once a day for 2 weeks, and the overall tolerance was good. This article reviewed the pharmacological action, pharmacokinetics, safety and clinical research progress in zuranolone.

  • Lin ZHU, Jiahao HU, Yuhan LIU, Fen LI, Chunlin JIN
    World Clinical Drug. 2023, 44(9): 994-1000.

    High-value orphan drugs for rare diseases can fill the clinical therapeutic gaps and significantly improve symptoms and patients' quality of life compared with standard treatment regimens. However, due to uncertainties in the number of patients, real-world efficacy and safety performance of drug, and fund budget impact and other factors, the decision-making risk of the medical insurance department is extremely uncertain. The high price also leads to the increasing difficulty of medical insurance access. Due to the particularity of rare diseases, there are certain limitations in drug list adjustments using the same selection and evaluation principle of conventional drugs and following the track of "strict access, loose extension" for high-value orphan drugs. According to the international experience, the medical insurance access of rare disease drugs needs a differentiated evaluation system. This article explored the dilemma of medical insurance access for high-value orphan drugs and analyzes the causes. Drawing on international experiences and combining with domestic medical insurance access practice, we put forward some ideas to improve the medical insurance access for high-value orphan drugs in China, in order to provide references for relevant department to make adjustments on the medical security for rare diseases and innovate the selection and evaluation mechanism, and further improve the accessibility of high-value orphan drugs for patients with rare diseases.

  • Jiajie XU, Dawei LYU, Chunlin JIN
    World Clinical Drug. 2023, 44(9): 1001-1005.

    This paper reviewed the system design and reform experience of health insurance and payment system in Chinese Taiwan from the aspects of the health insurance system and health insurance payment system, also provided references for the reform of medical and health system in Chinese mainland, including building a multi-channel financing system, continuously promoting the reform of medical insurance payment methods, introducing third-party institutions to formulate budget and payment standards, and strengthening medical service supervision and construction of information standardization.

  • Jiaqi LIANG, Caixia LI, Fanyu LIN, Yunxin JING, Pengcheng LIU
    World Clinical Drug. 2023, 44(9): 1006-1011.
    Objective

    To explore the way of carrying out the risk communication method of "patient safety medication guides" in China.

    Methods

    We reviewed the guidelines and regulations on "patient safety medication guides" issued by the drug regulatory authorities in typical countries, the United States and Japan, and the differences in their production, format content and other aspects were analyzed.

    Result

    Although both the United States and Japan implement the "patient safety medication guides" work, there are different regulatory requirements in various aspects. In addition, Japan does not have specific requirements for the format of patients safe medication, nor does it elaborate on the specific distribution requirements.

    Conclusion

    China could appropriately learn from the advanced experience of the United States and Japan, carry out the work of "patient safety medication guides", issue relevant guidelines as soon as possible, and specify the specific production requirements of "patient safety medication guides" in detail.

  • Misu XIAO, Wenqing ZHU, Yuanfeng NI, Qianyue YAO, Hongyi HU
    World Clinical Drug. 2023, 44(9): 1012-1016.
  • Changyuan LIU, Xin CHEN
    World Clinical Drug. 2023, 44(8): 767-772.

    Now there is growing evidence supporting the association between hypertension and tumors, and the two diseases have some common epidemiological and pathophysiological characteristics. Although antineoplastic drugs greatly improve survival rate of cancer patients, they increase the risk of cardiovascular disease including cardiac disease, thrombotic disease and hypertension. Studies have confirmed that a variety of antineoplastic drugs can cause or worsen hypertension, which in turn is an associated risk factor for certain cancers (e.g., renal cell carcinoma, colorectal cancer). In addition, drug interactions and some other adjuvant drugs in tumor therapy also have the potential to elevate the risk of hypertension. In January 2023, the American Heart Association published a scientific statement on cancer therapy-related hypertension, which aims to elucidate the epidemiology of antineoplastic drugs, the possible mechanisms that cause hypertension, and the diagnosis and management of hypertension due to cancer therapy drugs, and to identify important issues that need to be addressed and to provide recommendations and guidance. This article interpreted this scientific statement and provides a reference for the clinical diagnosis and treatment of cancer therapy-related hypertension in China.

  • Shaokun XU, Jianhong XIE
    World Clinical Drug. 2023, 44(8): 773-777.

    α-Receptor blockers are the classic drugs for hypertension, but they are no longer recommended as first-line antihypertensive agents in major hypertension guidelines. In recent years, with the continuous updating of relevant clinical trial results, the clinical application value of α-blockers has once again attracted attention, but its clinical application lacks sufficient and reasonable guidance, which hinders the important therapeutic effects of α-blockers. This article interpreted the recently published Chinese Expert Consensus on α-Blockers for Antihypertensive Therapy, in order to provide guidance for the rational application of α-receptor blockers.

  • Zekun FENG, Hao XUE
    World Clinical Drug. 2023, 44(8): 778-782.

    Pregnancy-induced hypertension syndrome (PIH) is a group of diseases that coexist with pregnancy and hypertension, which is one of the main causes of mortality in pregnant women, fetuses, and newborns. According to most current guidelines, PIH is classified as mild and severe hypertension based on blood pressure levels. Consensus has been reached on the treatment of pregnant women with severe hypertension (blood pressure during pregnancy≥160/110 mmHg). However, the treatment of pregnant women with mild hypertension remains controversial. Previous views had suggested that treatment of mild hypertension reduced the risk of severe hypertension, but not the incidence of adverse outcomes such as preeclampsia, premature delivery and growth restriction. However, recent studies have shown that reducing the target blood pressure during pregnancy is not only safe, but also beneficial for patients. The guidelines also recommend the timing, goals, and lower safety limits for initiating antihypertensive therapy for PIH. This article overviewed the effects of PIH on mothers and offspring, reviewed the progress of blood pressure management in patients with PIH, emphasized the management strategies of pregnant women with mild hypertension, so as to provide a basis for the management of PIH.

  • Boting CHEN, Xiaoyan GUO
    World Clinical Drug. 2023, 44(8): 783-790.
    Objective

    To investigate the effect of mollugin on the biological behavior of human hepatocellular carcinoma cells and its mechanism.

    Methods

    HepG2 cells were divided into control group, low, medium and high concentration of mollugin (40, 60 and 80 mmol/L) group, SN50 (36 µmol/L) group and high concentration of mollugin (80 mmol/L)+LPS (2.5 µmol/L) group. Cell counting kit-8 assay, clonal formation assay, flow cytometry and Transwell staining were used to detect the proliferation, apoptosis, invasion and migration of HepG2 cells. Western blotting was used to detect the protein expression in HepG2 cells.

    Results

    Compared with the control group, the cell proliferation inhibition rate, apoptosis rate, rabbit anti-Caspase-3 (Caspase-3), B-cell lymphoma 2 associated X protein (Bax), inhibitor of nuclear factor-κB (IκB-α) and Bax/B-cell lymphoma 2 (Bcl-2) in the low, medium, and high concentration of mollugin groups and SN50 group were increased (P<0.05). The number of clone cells, invasion and migration cells, Bcl-2, matrix metalloproteinase (MMP)-2, MMP-9, nuclear factor (NF)-κB and p-IκB-α were all decreased (P<0.05). Compared with the high concentration of mollugin group, the cell proliferation inhibition rate, apoptosis rate, Caspase-3, Bax, IκB-α and Bax/Bcl-2 in high concentration of mollugin+LPS group were decreased, the number of cloned cells, invasive and migratory cells, and the expression of MMP-2, MMP-9, NF-κB, Bcl-2 and p-IκB-α were all increased (P<0.05).

    Conclusion

    Mollugin may inhibit cell proliferation, invasion, migration and promote apoptosis of HepG2 cells by inhibiting NF-κB pathway, which is expected to become a targeted drug for the treatment of liver cancer.

News